Skip to content

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Association of Clinical Covariates With Non-insulin Diabetes Medication Initiation Using Electronic Medical Records (EMR)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02140645
Enrollment
166613
Registered
2014-05-16
Start date
2014-05-31
Completion date
2015-03-31
Last updated
2017-02-08

For informational purposes only โ€” not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation. This will include an assessment of how well these covariates are captured through claims data proxies, and their potential to confound comparative research of T2DM medications.

Detailed description

Purpose:

Interventions

DRUGlinagliptin

non-randomized

Sponsors

Eli Lilly and Company
CollaboratorINDUSTRY
Boehringer Ingelheim
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Dispensing of an oral or non-insulin injected hypoglycemic medication between May 2011 and June 2012 * Diagnosis of type 2 diabetes mellitus * Presence of electronic medical records (for the EMR-based subset)

Exclusion criteria

* Age \<18 at T2DM medication initiation * Missing or ambiguous age or sex information * At least one diagnosis of type 1 diabetes mellitus * Less than 6 months enrolment in the database preceding the date of the first dispensing * Prior use of the index drug

Design outcomes

Primary

MeasureTime frameDescription
Missing EMR (Electronic Medical Record) Characteristic: SmokingUp to 20 monthsThe missing EMR characteristic smoking defined as current, unknown, versus past/never smoker. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic smoking was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: Duration of DiabetesUp to 20 monthsThe missing EMR characteristic duration of diabetes defined as \>7, 5-6, 3-5, 1-3, \<1 (in years) in duration. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic duration of diabetes was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: Duration of Diabetes (Continuous)Up to 20 monthsThe missing EMR characteristic duration of diabetes defined as starting year/starting age of diabetes. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics duration of diabetes as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.
Missing EMR Characteristic: BMI (Body Mass Index)Up to 20 monthsThe missing EMR characteristic BMI defined as not obese, overweight, obese, severe obesity. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic BMI was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: BMI (Continuous)Up to 20 monthsThe missing EMR characteristic BMI is BMI value. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics BMI as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.
Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))Up to 20 monthsThe missing EMR characteristic HbA1c defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic HbA1c was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)Upto 20 monthsThe missing EMR characteristic eGFR defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic eGFR was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: Total CholesterolUp to 20 monthsThe missing EMR characteristic total cholesterol defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic total cholesterol was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: Systolic BP (Blood Pressure)Up to 20 monthsThe missing EMR characteristic systolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic systolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Missing EMR Characteristic: Diastolic BPUp to 20 monthsThe missing EMR characteristic diastolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic diastolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Binary EMR Characteristic: NeuropathyUp to 20 monthsThe missing EMR characteristic neuropathy defined as participants with any note of diabetic neuropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic neuropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Binary EMR Characteristic: NephropathyUpto 20 monthsThe missing EMR characteristic nephropathy defined as participants with any note of diabetic nephropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic nephropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Binary EMR Characteristic: RetinopathyUp to 20 monthsThe missing EMR characteristic retinopathy defined as participants with any note of diabetic retinopathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic retinopathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Binary EMR Characteristic: PancreatitisUp to 20 monthsThe missing EMR characteristic pancreatitis defined as participants with any note of prior pancreatitis. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic pancreatitis was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Countries

United States

Participant flow

Recruitment details

Existing data cohort design using data from the MarketScan database from May 2011 through December 2012. 492963 potential patients were identified in the database, but after removing patients who violated inclusion and exclusion criteria 166613 patients were actually analysed in the study.

Participants by arm

ArmCount
Linagliptin 1
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to any other DPP-4 (Dipeptidyl peptidase-4 inhibitors).
243
Any Other DPP-4
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication DPP-4 (Dipeptidyl peptidase-4 inhibitors).
3,041
Linagliptin 2
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to pioglitazone.
205
Pioglitazone
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication pioglitazone.
530
Linagliptin 3
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to second generation sulfonylurea.
150
Second Generation Sulfonylurea
Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication second generation sulfonylurea.
3,050
Total7,219

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004FG005
Overall StudyNot linked5,48961,6544,23613,8333,28670,896

Baseline characteristics

CharacteristicLinagliptin 1Any Other DPP-4Linagliptin 2PioglitazoneLinagliptin 3Second Generation SulfonylureaTotal
Age, Continuous56.1 Years
STANDARD_DEVIATION 11.6
54.8 Years
STANDARD_DEVIATION 11.2
55.2 Years
STANDARD_DEVIATION 11.7
54.7 Years
STANDARD_DEVIATION 11.1
54.7 Years
STANDARD_DEVIATION 11.8
54.8 Years
STANDARD_DEVIATION 11.7
54.9 Years
STANDARD_DEVIATION 11.5
Gender
Female
118 Participants1310 Participants101 Participants194 Participants74 Participants1332 Participants3129 Participants
Gender
Male
125 Participants1731 Participants104 Participants336 Participants76 Participants1718 Participants4090 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
โ€” / โ€”
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Binary EMR Characteristic: Nephropathy

The missing EMR characteristic nephropathy defined as participants with any note of diabetic nephropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic nephropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Upto 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (NUMBER)
Linagliptin 1Binary EMR Characteristic: Nephropathy5.8 Percentage of participants
Any Other DPP-4Binary EMR Characteristic: Nephropathy3.2 Percentage of participants
Linagliptin 2Binary EMR Characteristic: Nephropathy5.9 Percentage of participants
PioglitazoneBinary EMR Characteristic: Nephropathy4.3 Percentage of participants
Linagliptin 3Binary EMR Characteristic: Nephropathy4.7 Percentage of participants
Second Generation SulfonylureaBinary EMR Characteristic: Nephropathy3.0 Percentage of participants
Primary

Binary EMR Characteristic: Neuropathy

The missing EMR characteristic neuropathy defined as participants with any note of diabetic neuropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic neuropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (NUMBER)
Linagliptin 1Binary EMR Characteristic: Neuropathy9.9 Percentage of participants
Any Other DPP-4Binary EMR Characteristic: Neuropathy10.0 Percentage of participants
Linagliptin 2Binary EMR Characteristic: Neuropathy10.7 Percentage of participants
PioglitazoneBinary EMR Characteristic: Neuropathy11.3 Percentage of participants
Linagliptin 3Binary EMR Characteristic: Neuropathy12.0 Percentage of participants
Second Generation SulfonylureaBinary EMR Characteristic: Neuropathy11.0 Percentage of participants
Primary

Binary EMR Characteristic: Pancreatitis

The missing EMR characteristic pancreatitis defined as participants with any note of prior pancreatitis. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic pancreatitis was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (NUMBER)
Linagliptin 1Binary EMR Characteristic: Pancreatitis0.8 Percentage of participants
Any Other DPP-4Binary EMR Characteristic: Pancreatitis0.5 Percentage of participants
Linagliptin 2Binary EMR Characteristic: Pancreatitis1.0 Percentage of participants
PioglitazoneBinary EMR Characteristic: Pancreatitis0.2 Percentage of participants
Linagliptin 3Binary EMR Characteristic: Pancreatitis0.7 Percentage of participants
Second Generation SulfonylureaBinary EMR Characteristic: Pancreatitis0.5 Percentage of participants
Primary

Binary EMR Characteristic: Retinopathy

The missing EMR characteristic retinopathy defined as participants with any note of diabetic retinopathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic retinopathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (NUMBER)
Linagliptin 1Binary EMR Characteristic: Retinopathy1.2 Percentage of participants
Any Other DPP-4Binary EMR Characteristic: Retinopathy1.9 Percentage of participants
Linagliptin 2Binary EMR Characteristic: Retinopathy1.0 Percentage of participants
PioglitazoneBinary EMR Characteristic: Retinopathy2.8 Percentage of participants
Linagliptin 3Binary EMR Characteristic: Retinopathy1.3 Percentage of participants
Second Generation SulfonylureaBinary EMR Characteristic: Retinopathy1.7 Percentage of participants
Primary

Missing EMR Characteristic: BMI (Body Mass Index)

The missing EMR characteristic BMI defined as not obese, overweight, obese, severe obesity. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic BMI was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureGroupValue (NUMBER)
Linagliptin 1Missing EMR Characteristic: BMI (Body Mass Index)Obese35.4 Percentage of participants
Linagliptin 1Missing EMR Characteristic: BMI (Body Mass Index)Normal2.1 Percentage of participants
Linagliptin 1Missing EMR Characteristic: BMI (Body Mass Index)Underweight0.4 Percentage of participants
Linagliptin 1Missing EMR Characteristic: BMI (Body Mass Index)Severe Obesity16.5 Percentage of participants
Linagliptin 1Missing EMR Characteristic: BMI (Body Mass Index)Overweight11.5 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: BMI (Body Mass Index)Normal3.9 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: BMI (Body Mass Index)Obese35.1 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: BMI (Body Mass Index)Underweight0.1 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: BMI (Body Mass Index)Severe Obesity15.5 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: BMI (Body Mass Index)Overweight11.8 Percentage of participants
Linagliptin 2Missing EMR Characteristic: BMI (Body Mass Index)Normal2.0 Percentage of participants
Linagliptin 2Missing EMR Characteristic: BMI (Body Mass Index)Obese35.1 Percentage of participants
Linagliptin 2Missing EMR Characteristic: BMI (Body Mass Index)Severe Obesity16.1 Percentage of participants
Linagliptin 2Missing EMR Characteristic: BMI (Body Mass Index)Overweight13.7 Percentage of participants
Linagliptin 2Missing EMR Characteristic: BMI (Body Mass Index)Underweight0.5 Percentage of participants
PioglitazoneMissing EMR Characteristic: BMI (Body Mass Index)Overweight15.5 Percentage of participants
PioglitazoneMissing EMR Characteristic: BMI (Body Mass Index)Underweight0.0 Percentage of participants
PioglitazoneMissing EMR Characteristic: BMI (Body Mass Index)Normal3.4 Percentage of participants
PioglitazoneMissing EMR Characteristic: BMI (Body Mass Index)Obese29.6 Percentage of participants
PioglitazoneMissing EMR Characteristic: BMI (Body Mass Index)Severe Obesity10.9 Percentage of participants
Linagliptin 3Missing EMR Characteristic: BMI (Body Mass Index)Obese36.0 Percentage of participants
Linagliptin 3Missing EMR Characteristic: BMI (Body Mass Index)Underweight0.7 Percentage of participants
Linagliptin 3Missing EMR Characteristic: BMI (Body Mass Index)Severe Obesity16.0 Percentage of participants
Linagliptin 3Missing EMR Characteristic: BMI (Body Mass Index)Normal2.7 Percentage of participants
Linagliptin 3Missing EMR Characteristic: BMI (Body Mass Index)Overweight10.7 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Body Mass Index)Underweight0.1 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Body Mass Index)Obese34.2 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Body Mass Index)Normal4.0 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Body Mass Index)Severe Obesity15.4 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Body Mass Index)Overweight14.0 Percentage of participants
Primary

Missing EMR Characteristic: BMI (Continuous)

The missing EMR characteristic BMI is BMI value. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics BMI as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: BMI (Continuous)36.3 Kg/m^2Standard Deviation 8.5
Any Other DPP-4Missing EMR Characteristic: BMI (Continuous)35.5 Kg/m^2Standard Deviation 8
Linagliptin 2Missing EMR Characteristic: BMI (Continuous)36.1 Kg/m^2Standard Deviation 8.8
PioglitazoneMissing EMR Characteristic: BMI (Continuous)34.2 Kg/m^2Standard Deviation 7
Linagliptin 3Missing EMR Characteristic: BMI (Continuous)36.6 Kg/m^2Standard Deviation 9.2
Second Generation SulfonylureaMissing EMR Characteristic: BMI (Continuous)35.1 Kg/m^2Standard Deviation 7.8
Primary

Missing EMR Characteristic: Diastolic BP

The missing EMR characteristic diastolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic diastolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: Diastolic BP79.5 mmHgStandard Deviation 10.6
Any Other DPP-4Missing EMR Characteristic: Diastolic BP78.8 mmHgStandard Deviation 10
Linagliptin 2Missing EMR Characteristic: Diastolic BP80.0 mmHgStandard Deviation 10.2
PioglitazoneMissing EMR Characteristic: Diastolic BP79.3 mmHgStandard Deviation 10.6
Linagliptin 3Missing EMR Characteristic: Diastolic BP80.0 mmHgStandard Deviation 10.5
Second Generation SulfonylureaMissing EMR Characteristic: Diastolic BP79.6 mmHgStandard Deviation 10.5
Primary

Missing EMR Characteristic: Duration of Diabetes

The missing EMR characteristic duration of diabetes defined as \>7, 5-6, 3-5, 1-3, \<1 (in years) in duration. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic duration of diabetes was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureGroupValue (NUMBER)
Linagliptin 1Missing EMR Characteristic: Duration of Diabetes5.00-6.99 years4.9 Percentage of participants
Linagliptin 1Missing EMR Characteristic: Duration of Diabetes1.00-2.99 years11.5 Percentage of participants
Linagliptin 1Missing EMR Characteristic: Duration of DiabetesLess than 1 year11.9 Percentage of participants
Linagliptin 1Missing EMR Characteristic: Duration of Diabetes7+ years5.3 Percentage of participants
Linagliptin 1Missing EMR Characteristic: Duration of Diabetes3.00-4.99 years7.8 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: Duration of Diabetes1.00-2.99 years14.2 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: Duration of Diabetes5.00-6.99 years5.1 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: Duration of DiabetesLess than 1 year13.7 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: Duration of Diabetes7+ years5.3 Percentage of participants
Any Other DPP-4Missing EMR Characteristic: Duration of Diabetes3.00-4.99 years7.8 Percentage of participants
Linagliptin 2Missing EMR Characteristic: Duration of Diabetes1.00-2.99 years11.2 Percentage of participants
Linagliptin 2Missing EMR Characteristic: Duration of Diabetes5.00-6.99 years3.9 Percentage of participants
Linagliptin 2Missing EMR Characteristic: Duration of Diabetes7+ years5.4 Percentage of participants
Linagliptin 2Missing EMR Characteristic: Duration of Diabetes3.00-4.99 years7.8 Percentage of participants
Linagliptin 2Missing EMR Characteristic: Duration of DiabetesLess than 1 year12.7 Percentage of participants
PioglitazoneMissing EMR Characteristic: Duration of Diabetes3.00-4.99 years8.3 Percentage of participants
PioglitazoneMissing EMR Characteristic: Duration of DiabetesLess than 1 year11.1 Percentage of participants
PioglitazoneMissing EMR Characteristic: Duration of Diabetes1.00-2.99 years10.0 Percentage of participants
PioglitazoneMissing EMR Characteristic: Duration of Diabetes5.00-6.99 years5.7 Percentage of participants
PioglitazoneMissing EMR Characteristic: Duration of Diabetes7+ years5.8 Percentage of participants
Linagliptin 3Missing EMR Characteristic: Duration of Diabetes5.00-6.99 years4.0 Percentage of participants
Linagliptin 3Missing EMR Characteristic: Duration of DiabetesLess than 1 year16.0 Percentage of participants
Linagliptin 3Missing EMR Characteristic: Duration of Diabetes7+ years5.3 Percentage of participants
Linagliptin 3Missing EMR Characteristic: Duration of Diabetes1.00-2.99 years12.7 Percentage of participants
Linagliptin 3Missing EMR Characteristic: Duration of Diabetes3.00-4.99 years7.3 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: Duration of DiabetesLess than 1 year15.4 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: Duration of Diabetes5.00-6.99 years4.8 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: Duration of Diabetes1.00-2.99 years13.6 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: Duration of Diabetes7+ years4.8 Percentage of participants
Second Generation SulfonylureaMissing EMR Characteristic: Duration of Diabetes3.00-4.99 years8.4 Percentage of participants
Primary

Missing EMR Characteristic: Duration of Diabetes (Continuous)

The missing EMR characteristic duration of diabetes defined as starting year/starting age of diabetes. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics duration of diabetes as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: Duration of Diabetes (Continuous)3.5 MonthsStandard Deviation 3.7
Any Other DPP-4Missing EMR Characteristic: Duration of Diabetes (Continuous)3.1 MonthsStandard Deviation 3.3
Linagliptin 2Missing EMR Characteristic: Duration of Diabetes (Continuous)3.4 MonthsStandard Deviation 3.7
PioglitazoneMissing EMR Characteristic: Duration of Diabetes (Continuous)3.5 MonthsStandard Deviation 3.1
Linagliptin 3Missing EMR Characteristic: Duration of Diabetes (Continuous)3.0 MonthsStandard Deviation 3.4
Second Generation SulfonylureaMissing EMR Characteristic: Duration of Diabetes (Continuous)2.9 MonthsStandard Deviation 3
Primary

Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)

The missing EMR characteristic eGFR defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic eGFR was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Upto 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)103.8 ml/min per 1.73 m^2Standard Deviation 19.2
Any Other DPP-4Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)107.0 ml/min per 1.73 m^2Standard Deviation 18
Linagliptin 2Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)104.9 ml/min per 1.73 m^2Standard Deviation 18.7
PioglitazoneMissing EMR Characteristic: eGFR (Glomerular Filtration Rate)108.7 ml/min per 1.73 m^2Standard Deviation 19.3
Linagliptin 3Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)105.5 ml/min per 1.73 m^2Standard Deviation 18.5
Second Generation SulfonylureaMissing EMR Characteristic: eGFR (Glomerular Filtration Rate)106.8 ml/min per 1.73 m^2Standard Deviation 18.7
Primary

Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))

The missing EMR characteristic HbA1c defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic HbA1c was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))8.2 PercentageStandard Deviation 1.4
Any Other DPP-4Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))8.6 PercentageStandard Deviation 1.9
Linagliptin 2Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))8.3 PercentageStandard Deviation 1.4
PioglitazoneMissing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))9.0 PercentageStandard Deviation 2.2
Linagliptin 3Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))8.0 PercentageStandard Deviation 1.5
Second Generation SulfonylureaMissing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))8.8 PercentageStandard Deviation 2
Primary

Missing EMR Characteristic: Systolic BP (Blood Pressure)

The missing EMR characteristic systolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic systolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: Systolic BP (Blood Pressure)130.2 mmHgStandard Deviation 16.3
Any Other DPP-4Missing EMR Characteristic: Systolic BP (Blood Pressure)129.7 mmHgStandard Deviation 15.7
Linagliptin 2Missing EMR Characteristic: Systolic BP (Blood Pressure)131.0 mmHgStandard Deviation 16.1
PioglitazoneMissing EMR Characteristic: Systolic BP (Blood Pressure)131.5 mmHgStandard Deviation 17.2
Linagliptin 3Missing EMR Characteristic: Systolic BP (Blood Pressure)131.2 mmHgStandard Deviation 17.3
Second Generation SulfonylureaMissing EMR Characteristic: Systolic BP (Blood Pressure)131.3 mmHgStandard Deviation 17
Primary

Missing EMR Characteristic: Total Cholesterol

The missing EMR characteristic total cholesterol defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic total cholesterol was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureValue (MEAN)Dispersion
Linagliptin 1Missing EMR Characteristic: Total Cholesterol188.8 mg/dlStandard Deviation 59.7
Any Other DPP-4Missing EMR Characteristic: Total Cholesterol177.6 mg/dlStandard Deviation 47
Linagliptin 2Missing EMR Characteristic: Total Cholesterol189.7 mg/dlStandard Deviation 62.9
PioglitazoneMissing EMR Characteristic: Total Cholesterol185.8 mg/dlStandard Deviation 58.8
Linagliptin 3Missing EMR Characteristic: Total Cholesterol194.6 mg/dlStandard Deviation 53.1
Second Generation SulfonylureaMissing EMR Characteristic: Total Cholesterol185.8 mg/dlStandard Deviation 50.8
Primary

Missing EMR (Electronic Medical Record) Characteristic: Smoking

The missing EMR characteristic smoking defined as current, unknown, versus past/never smoker. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic smoking was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.

Time frame: Up to 20 months

Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.

ArmMeasureGroupValue (NUMBER)
Linagliptin 1Missing EMR (Electronic Medical Record) Characteristic: SmokingCurrent9.1 Percentage of participants
Linagliptin 1Missing EMR (Electronic Medical Record) Characteristic: SmokingPast12.3 Percentage of participants
Linagliptin 1Missing EMR (Electronic Medical Record) Characteristic: SmokingNever32.9 Percentage of participants
Linagliptin 1Missing EMR (Electronic Medical Record) Characteristic: SmokingUnknown5.8 Percentage of participants
Any Other DPP-4Missing EMR (Electronic Medical Record) Characteristic: SmokingNever35.5 Percentage of participants
Any Other DPP-4Missing EMR (Electronic Medical Record) Characteristic: SmokingPast12.2 Percentage of participants
Any Other DPP-4Missing EMR (Electronic Medical Record) Characteristic: SmokingCurrent7.6 Percentage of participants
Any Other DPP-4Missing EMR (Electronic Medical Record) Characteristic: SmokingUnknown4.9 Percentage of participants
Linagliptin 2Missing EMR (Electronic Medical Record) Characteristic: SmokingUnknown6.3 Percentage of participants
Linagliptin 2Missing EMR (Electronic Medical Record) Characteristic: SmokingNever32.7 Percentage of participants
Linagliptin 2Missing EMR (Electronic Medical Record) Characteristic: SmokingPast12.2 Percentage of participants
Linagliptin 2Missing EMR (Electronic Medical Record) Characteristic: SmokingCurrent10.7 Percentage of participants
PioglitazoneMissing EMR (Electronic Medical Record) Characteristic: SmokingCurrent7.9 Percentage of participants
PioglitazoneMissing EMR (Electronic Medical Record) Characteristic: SmokingUnknown5.1 Percentage of participants
PioglitazoneMissing EMR (Electronic Medical Record) Characteristic: SmokingPast10.2 Percentage of participants
PioglitazoneMissing EMR (Electronic Medical Record) Characteristic: SmokingNever30.8 Percentage of participants
Linagliptin 3Missing EMR (Electronic Medical Record) Characteristic: SmokingNever34.7 Percentage of participants
Linagliptin 3Missing EMR (Electronic Medical Record) Characteristic: SmokingUnknown6.0 Percentage of participants
Linagliptin 3Missing EMR (Electronic Medical Record) Characteristic: SmokingPast10.7 Percentage of participants
Linagliptin 3Missing EMR (Electronic Medical Record) Characteristic: SmokingCurrent11.3 Percentage of participants
Second Generation SulfonylureaMissing EMR (Electronic Medical Record) Characteristic: SmokingPast10.9 Percentage of participants
Second Generation SulfonylureaMissing EMR (Electronic Medical Record) Characteristic: SmokingNever33.3 Percentage of participants
Second Generation SulfonylureaMissing EMR (Electronic Medical Record) Characteristic: SmokingUnknown6.5 Percentage of participants
Second Generation SulfonylureaMissing EMR (Electronic Medical Record) Characteristic: SmokingCurrent9.4 Percentage of participants

Source: ClinicalTrials.gov ยท Data processed: Feb 4, 2026